BioSpace News Archive

Pipeline Therapeutics today announced that the first subject was dosed in the Phase 1 clinical trial of PIPE-791 in healthy volunteers.

Charles River Laboratories International, Inc. (NYSE: CRL) announced the planned openings of Charles River Accelerator and Development Lab (CRADL®) locations in Seattle and Philadelphia, expanding contract vivarium space for the biopharmaceutical industry.

Anbio, a leading provider of innovative diagnostic solutions, made a successful market presence at the 2023 American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced $20 million in Series A extension funding committed by Apple Tree Partners (ATP).

C4X Discovery Holdings plc, a pioneering Drug Discovery company, announces the execution of an asset purchase agreement for Indivior PLC to acquire the proprietary rights to C4XD’s oral Orexin-1 receptor antagonist, C4X_3256 for substance use disorder, for £15.95 million.

Mainz Biomed NV announced that London-based Marylebone Laboratory has introduced ColoAlert®, Mainz Biomed’s flagship product, a highly effective and user-friendly at-home detection test for colorectal cancer - to its extensive UK and international customer base.

MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will participate in one-on-one meetings at the 2023 Wedbush PacGrow Healthcare Conference on Tuesday, August 8, 2023 at the Lotte Palace in New York City.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced that Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at the Canaccord Genuity 43rd Annual Growth Conference, which will be held from August 7-10, 2023.

Vizient, Inc. projects a 3.42% increase in hospital pharmaceutical spend in its Summer Pharmacy Market Outlook, released July 31.

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in the following August investor conferences: